Operator of a clinical-stage biopharmaceutical company intended to develop antiviral agents against novel targets in the treatment of hepatitis. The company's focuses on the development of treatments for strains of hepatitis. The company's clinical-stage biopharmaceutical services includes preclinical new chemical entities (NCEs) designed for antiviral activity against Hepatitis C, Hepatitis D and an array of other viruses.
Generating Revenue
Publicly Held
Venture Capital-Backed
The company (NASDAQ:EIGR) recieved $3 million of development capital from HBM Healthcare Investments on May 2, 2016. Previously, the company acquired Celladon through a reverse merger, resulting in the combined entity trading on the NASDAQ Stock Exchange under the ticker symbol EIGR on March 22, 2016.
Add a review